Elicio to advance pancreatic, HPV vaccines, CAR T booster with $33M B round

Six months after raising a $30 million series A round, Elicio has added $33 million via its B round to begin Phase I/II testing of its KRAS-driven cancer vaccine ELI-002 and advance its other immunotherapies.

Elicio Therapeutics’ Amphiphile platform, which attaches antigens to an

Read the full 438 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers